NRC FORM 591M F	PART 1		U.S. NU	CLEAR REGULATOR	RY COMMISSION		
(07-2012) 10 CFR 2.201	SAFETY INSPECTION	REPORT AN	D COMPLIANCE IN	SPECTION			
1. LICENSEE/LOCAT	ION INSPECTED:	· · · · · · · · · · · · · · · · · · ·	2. NRC/REGIONAL OFFICE				
Memorial Hospital			Region III				
615 North Michigan Street			U. S. Nuclear Regulatory Commission				
South Bend, IN 46601			2443 Warrenville Road, Suite 210				
			Lisle, IL 60532-4352				
REPORT NUMBER	, ,	LA LIGENSE MUNICES		Le DATE(O) OF MICHE	TION		
'		4. LICENSE NUMBER			5. DATE(S) OF INSPECTION		
030-17335		13-18881-01		July 9-11.	2018		
Regulatory Commis procedures and rep	an examination of the activities conduction (NRC) rules and regulations and the resentative records, interviews with permited in the inspection findings, no violations is violation(s) closed.	ne conditions of your l sonnel, and observati	icense. The inspection consist	ed of selective examin	ations of		
3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.							
Non-cited violation(s) were discussed involving the following requirement(s):							
cited in a with 10 0	nis inspection, certain of your activities, accordance with NRC Enforcement Poli CFR 19.11. Ins and Corrective Actions)						
	04-	4 of O	Alua A Alua				
corrective actions is	ota vithin 30 days, the actions described by made in accordance with the requireme iance will be achieved). I understand the	ents of 10 CFR 2.201	vill be taken to correct the violat (corrective steps already taken	, corrective steps whic	h will be taken,		
TITLE	PRINTED NAME		SIGNATURE		DATE		
LICENSEE'S REPRESENTATIVE							
NRC INSPECTOR	Ryan Craffey		Pol Col	# &]	7/11/18		
BRANCH CHIEF	Aaron McCraw		21-2	for ATM	8/15/18		
	<u> </u>	· · · · · · · · · · · · · · · · · · ·	v				

NRC FORM 591M PART 3 (07-2012))		CLEAR REGULATORY COMMISSION				
10 CFR 2.201								
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATION INSPECT	ED:		2. NRC/REGIONAL OFFICE					
Memorial Hospital 615 North Michigan Stree South Bend, IN 46601	.		Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352					
REPORT NUMBER(S) 2018001								
3. DOCKET NUMBER(S)		4. LICENSE NUMBER(S)		5. DATE(S) OF INSPECTION				
030-17335		13-18881-01		July 9-11, 2018				
6. INSPECTION PROCEDURES USE	:D	7. INSPECTION FOCUS AREAS						
87131, 87132		All						
SUPPLEMENTAL INSPECTION INFORMATION								
1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTAC	Т	4 TELEPHONE NUMBER				
02230	2	Daniel Archambeault, MS - RSO		(574) 204-7215				
✓ Main Office Inspection Next Inspection Date: 07/09/2020 ✓ Field Office Inspection 610 N Michigan Avenue & 301 E Day Road								
Temporary Job Site Inspection								

PROGRAM SCOPE

This was an unannounced routine inspection of a regional hospital authorized to use byproduct material for diagnostic and therapeutic medical purposes at its campus in South Bend, Indiana, and at a satellite facility in Mishawaka. At the main hospital (615 North Michigan), the licensee operated its HDR unit weekly to perform gynecological, breast, and prostate cancer treatments, performed occasional permanent implant brachytherapy for prostate cancer, and performed around a dozen diagnostic administrations per day and 8-10 therapeutic administrations per quarter at its nuclear medicine laboratory. At Beacon Advanced Cardiovascular Specialists (610 N Michigan), the licensee performed 4-6 cardiac stress tests each morning, and at the Memorial Regional Cancer center (301 E Day), the licensee performed around four PET scans each morning. The licensee has not performed any administrations of Y-90 microspheres since before the last inspection. Note that the licensee's RSO currently works most days at the facility on Day Road, but will be moving back (along with the PET lab) to the main hospital later in 2018.

PERFORMANCE OBSERVATIONS: The inspector toured all three facilities to evaluate the licensee's measures for materials security, hazard communication, and exposure control. The inspector conducted independent and confirmatory surveys of these facilities, and found no evidence of residual contamination or exposures to members of the public in excess of regulatory limits. The inspector observed a prostate HDR treatment (including HDR unit spot checks and treatment planning), a therapeutic administration of I-131, and several diagnostic administrations at each facility. The inspector also observed the conduct of area surveys and receipt of packages containing licensed material, HDR annual drills, and a demonstration of HDR unit full calibrations. The inspector interviewed members of the licensee's staff to discuss procedures for the safe use of licensed material, ALARA practices, and oversight of the radiation safety program. The inspector reviewed written directives as well as planning and verification documentation for a selection of HDR treatments, prostate seed implants, and I-131 and Ra-223 therapies performed since the last inspection. The inspector found that the licensee's procedures provided high confidence that such treatments were performed in accordance with these written directives. The inspector also reviewed a selection of other records, including RSC meeting minutes, health physics consultant audits, HDR spot check and full calibration records, personnel dosimetry, and training documentation.

No violations of NRC requirements were identified as a result of this inspection.

6w for ATM 8/15/18